Bionaturis (BNT-MAB), an international reference company developing vaccines for aquiculture, has signed a contract with a multinational veterinarian company to evaluate the efficacy and safety of a FLYLIFE-produced vaccine intended to be used against the most devastating diseases affecting the salmon industry.

During the first half (H1) of 2014 the multinational company will perform in vivo exploratory trials in salmons. The salmon industry is, along with the carp one, one of the biggest aquiculture industries in the world, having reached annual figures greater than 11 billion dollars since 2007. Norway with 33% and Chile with 31% lead world production. Throughout history, several episodes of pandemics, mainly of the ISA (Infectious Salmon Anemia) virus, have generated significant losses. Because of that, the search of new prevention and therapeutic solutions to fight those diseases affecting the sector is one of the salmon industry priorities.

Javier Gallastegui, managing director of Bionaturis, states: “the worldwide positioning we have achieved as a supplier of aquaculture vaccines is confirmed with contracts of this kind. If the trials are successful we could get incomes between 10 and 15 million dollars in royalties in the years following the vaccine launch to the market”.Bionaturis (BNT-MAB), an international reference company developing vaccines for aquiculture, has signed a contract with a multinational veterinarian company to evaluate the efficacy and safety of a FLYLIFE-produced vaccine intended to be used against the most devastating diseases affecting the salmon industry.

During the first half (H1) of 2014 the multinational company will perform in vivo exploratory trials in salmons. The salmon industry is, along with the carp one, one of the biggest aquiculture industries in the world, having reached annual figures greater than 11 billion dollars since 2007. Norway with 33% and Chile with 31% lead world production. Throughout history, several episodes of pandemics, mainly of the ISA (Infectious Salmon Anemia) virus, have generated significant losses. Because of that, the search of new prevention and therapeutic solutions to fight those diseases affecting the sector is one of the salmon industry priorities.

Javier Gallastegui, managing director of Bionaturis, states: “the worldwide positioning we have achieved as a supplier of aquaculture vaccines is confirmed with contracts of this kind. If the trials are successful we could get incomes between 10 and 15 million dollars in royalties in the years following the vaccine launch to the market”.